// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

A Post Hoc Analysis of SUSTAIN 9

BERNARD ZINMAN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diabetic ketoacidosis

Luseogliflozin

PIONEER 8

BERNARD ZINMAN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Semaglutide

The DISPELTM Study

REEMA MODY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The SPARE Study

RUTH E. BROWN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Semaglutide

A Subanalysis of BALANCE 205

RICHARD E. PRATLEY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

Efpeglenatide

Safety and Efficacy of a Novel Basal-Bolus Insulin Delivery Device (IDD) in Adults with T2D Using Rapid-Acting or Regular Human Insulin

RONNIE ARONSON - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Recombinant insulin

Insulin Pump Catheters Can Be Worn Much More Than the Recommended Three Days

JEAN-LUC ARDILOUZE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

N/A

Towards Prolongation of Insulin Pump Catheters Wearing Time Using a Mixture of Insulin and a Nonsteroidal Anti-inflammatory Drug

JEAN-LUC ARDILOUZE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

Ketorolac

The BRIGHT and EDITION 3 Trials

LORI BERARD - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Insulin glargine

Exploratory Analyses from BRIGHT

RONAN ROUSSEL - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Insulin glargine

Patient Characteristics and Clinical Outcomes

STEWART B. HARRIS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diabetes

Insulin glargine

The LIGHTNING Study

IRENE HRAMIAK - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Renal disease

Insulin glargine

SGLT2 Inhibition Increases Serum Copeptin in Adults with Type 1 Diabetes (T1D)

YULIYA LYTVYN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic nephropathy

BI-10773

SGLT2 Inhibition (SGLT2i) Mediated Urinary Glucose Excretion (UGE) Associations with Metabolic and Renal Hemodynamic Parameters

YULIYA LYTVYN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hyperglycemia

BI-10773

Lessons from Diabetic Mice

MARGARITA BECKERMAN - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

A Modeling and Simulation Approach to Further Characterize the Efficacy of Low-Dose Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes (T1DM)

BRUCE A. PERKINS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diabetic ketoacidosis

BI-10773

The Impact of Sotagliflozin on Renal Function, Albuminuria, and Blood Pressure in Adults with Type 1 Diabetes (T1D)

DANIËL H. VAN RAALTE - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic nephropathy

LX4211

Analysis of Patient Preferences for Adjunct Therapy to Insulin in T1D

BRUCE A. PERKINS - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

BI-10773

Sotagliflozin Reduces Glucose Variability and Risk for Hyperglycemia in Adults with Type 1 Diabetes

BORIS KOVATCHEV - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 1 diabetes mellitus

LX4211

Two-Year Effects of Ertugliflozin on Renal Function

DAVID CHERNEY - American Diabetes Association (ADA) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Albuminuria

Ertugliflozin

Copyright © 2026. QuantiNova All rights reserved